No CrossRef data available.
Article contents
Neuroleptics: preclinical and clinical differences
Published online by Cambridge University Press: 18 September 2015
Summary
Neuroleptics: preclinical and clinical differences
In this review we propose that the clinical and preclinical effects of neuroleptic drugs justify a distinction between classical and atypical neuroleptic drugs. Binding, biochemical, electrophysiological and behavioural studies have revealed clearcut differences between classical neuroleptics (like haloperidol and fluphenazine) and atypical neuroleptics (such as clozapine, thioridazine and remoxipride). These large differences are likely due to differences in the workingmechanisms. In view of the clinical relevance of these findings it is therefore both justified and essential to subdivide the neuroleptics in two distinct groups: the classical neuroleptics and the atypical neuroleptics.
Keywords
- Type
- Research Article
- Information
- Copyright
- Copyright © Scandinavian College of Neuropsychopharmacology 1992
References
Literatuur
6.Alfredsson, G, Harnryd, C, Wiesel, F. Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients: relationship to drug concentrations. Psychopharmacol 1984;85:8–13.CrossRefGoogle Scholar
7.Lambert, P, Re vol, L.Classification psychopharmacologique et clinique des different neuroleptiques indications generales dans les psychoses, Presse Med 1960; 68:1509–11.Google Scholar
8.Bobon, J, Bobon, D, Pinchard, A, et al.A new comparative physiognomy of neuroleptics: A collaborative clinical report. Acta psychiat belg 1972;72:542–54.Google ScholarPubMed
9.Fischer-Cornellson, K, Ferner, U, Steiner, H.Multifokale Psychopharmakaprüfung. Arzneim Forsch 1974; 24:1706–24.Google Scholar
12.Pi, E, Simpson, G.Atypical neuroleptics: clozapine and the benza-mides in the prevention of tardive dyskinesia. Mod Probl Pharmacopsychiat 1983; 21:80–6.CrossRefGoogle ScholarPubMed
13.Cole, J, Clyde, D.Extrapyramidal side-effects and clinical response to the phenothiazines. Rev can Biol 1961; 20:565–74.Google Scholar
18.Sayers, A, Amsler, H.Clozapine In: Goldberg, M ed. Pharmacological and biochemical Properties of Drug Substances. Vol 1. New York: Amer Pharmaceut Soc, 1977: 1–31.Google Scholar
19.Kane, J, Honigfeld, G, Singer, J, Meitzer, H.Clozapine in treatment resistant schizophrenics. Psychopharmacol Bull 1988; 24:63–7.Google ScholarPubMed
20.Baldessarini, R, Frankenburg, F.Clozapine, a novel antipsychotic agent. New Eng J Med, 1991;324:746–54.Google ScholarPubMed
22.Den Boer, J, Westenberg, H, Louwerens, J, Slooff, C.Over de klinische betekenis van atypische neuroleptica. Acta Neuropsychiat 1991; 3:55–60.Google Scholar
23.Creese, I, Burt, D, Snyder, S.Dopamine receptor binding predicts clinical and pharmacological potenties of antischizophrenic drugs. Science 1976; 192:481–3.CrossRefGoogle Scholar
24.Seeman, P, Lee, T, Choa-Wong, M, Wong, K.Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261:717–9.CrossRefGoogle ScholarPubMed
26.Snyder, S, Greenberg, D, Yamamura, H.Antischizophrenic drugs and brain cholinergic receptors. Arch gen Psychiat 1974; 31:58–61.CrossRefGoogle ScholarPubMed
30.Meitzer, H, Matsubara, S, Lee, J.Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-l, D-2 and serotonin2 pKi values. J Pharm exp Ther 1989; 251:238–46.Google Scholar
34.Cools, A, van Rossum, J.Excitation-mediating and inhibition-mediating dopamine receptors: a new concept towards a better understanding of electrophysiological, biochemical, functional and clinical data. Psychopharmacol 1976; 45:243–54.CrossRefGoogle ScholarPubMed
39.Ellenbroek, B, Artz, M, Cools, A.The involvement of dopamine D1, and D2 receptors in the effects of the classical neuroleptic halope-ridol and the atypical neuroleptic clozapine. Europ J Pharmacol 1991; 196:103–8.CrossRefGoogle ScholarPubMed
40.Andersen, P, Nielsen, B, Gronvald, F, Braestrup, C.Some atypical neuroleptics inhibit [3H/SCH 23390 binding in vivo. Europ J Pharmacol 1986; 120:143–4.CrossRefGoogle ScholarPubMed
50.Altar, C, Wasley, A, Neale, R, Stone, G.Typical and atypical antipsychotic occupancy of D2 and S2 receptors: An autoradiographic analysis on rat brain. Brain Res Bull 1986; 16:517–25.CrossRefGoogle ScholarPubMed
51.Westerink, B, Korf, J.Influence of drugs on striatal and limbic homovanillic acid concentration in the rat brain. Europ J Pharmacol 1975; 33: 31–40.CrossRefGoogle ScholarPubMed
62.Chiodo, L, Bunney, B.Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3:1607–19.CrossRefGoogle ScholarPubMed
63.White, F, Wang, R.Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983; 211:1054–6.CrossRefGoogle Scholar
71.Ögren, S, Hall, H, Köhler, C, Magnusson, O, Sjöstrand, S.The selective dopamine D2 antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacol 1986; 90:287–94.CrossRefGoogle ScholarPubMed
73.Moore, N, Gershon, S.Which atypical antipsychotics are identified by screening tests? Clin Neuropharmacol 1989; 12:167–84.CrossRefGoogle ScholarPubMed
77.Ellenbroek, B, Peeters, B, Honig, W, Cools, A.The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacol 1987; 93:343–8.CrossRefGoogle Scholar
82.Janssen, P, Niemegeers, C, Schellekens, K, Lenaerts, F.Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part IV:An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-induced ‘chewing’ and ‘agitation’ in rats. Arzneim Forsch 1967; 17:841–54.Google Scholar